ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 30, 2009, Pages 12465-12470

  Zong, Yang ^a   Xin, Li ^a,b   Goldstein, Andrew S ^a   Lawson, Devon A ^a   Teitell, Michael A ^a   Witte, Owen N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AKT; Androgen receptor; ERG; Prostate cancer; PTEN

Indexed keywords

ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL REGENERATION; EPITHELIUM HYPERPLASIA; GENE FUNCTION; GENE FUSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LENTIVIRINAE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA-BINDING PROTEINS; EPITHELIAL CELLS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA6; KERATIN-5; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MUTATION; ONCOGENE PROTEINS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 68149159298     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905931106     Document Type: Article

References (45)

1. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138-141.
2. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799.
3. Abate-Shen C, Shen MM (2000) Molecular genetics of prostate cancer. Genes Dev 14:2410-2434.
4. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
5. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2006) Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 12:529-536.
6. Tomlins SA, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
7. Tomlins SA, et al. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396-3400.
8. Tomlins SA, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595-599.
9. Helgeson BE, et al. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68:73-80.
10. Hermans KG, et al. (2006) TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66:10658-10663.
11. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8:497-511.
12. Perner S, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66:8337-8341.
13. Klezovitch O, et al. (2008) Acausal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105-2110.
14. Zhang J, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710.
15. Wu X, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61-69.
16. Tomlins SA, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188.
17. Carver BS, et al. (2009) ETS rearrangements and prostate cancer initiation. Nature 457:E1; discussion E2-3.
18. King JC, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41:524-526.
19. Xin L, Ide H, Kim Y, Dubey P, Witte ON (2003) In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci USA 100(Suppl 1):11896-11903.
20. Mosquera JM, et al. (2007) Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 212:91-101.
21. Stingl J, et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439:993-997.
22. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON (2007) Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 104:181-186.
23. Sun C, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27:5348-5353.
24. Verger A, et al. (2001) Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation. J Biol Chem 276:17181-17189.
25. Downing SR, Russell PJ, Jackson P (2003) Alterations of p53 are common in early stage prostate cancer. Can J Urol 10:1924-1933.
26. Chen Z, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730.
27. Zhou Z, et al. (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898.
28. Portella G, et al. (2001) Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice. Oncol Res 12:347-354.
29. Yoshimoto M, et al. (2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169:128-137.
30. Xin L, Lawson DA, Witte ON (2005) The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 102:6942-6947.
31. Xin L, et al. (2006) Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 103:7789 -7794.
32. Majumder PK, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 100:7841-7846.
33. Wang S, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221.
34. Shaffer DR, Pandolfi PP (2006) Breaking the rules of cancer. Nat Med 12:14-15.
35. Chen CD, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
36. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361:955-964.
37. Gao J, Arnold JT, Isaacs JT (2001) Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61:5038-5044.
38. Bergerat JP, Ceraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30:145-157.
39. Pereira DS, et al. (1998) Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc Natl Acad Sci USA 95:8239-8244.
40. Han G, et al. (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156.
41. Cai C, Hsieh CL, Shemshedini L (2007) c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol Cancer Res 5:725-735.
42. Garlich JR, et al. (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68:206-215.
43. Maira SM, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863.
44. Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448.
45. Memarzadeh S, et al. (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12:572-585.